Indexed corpus
Sources (30)
All documents are synthetic and were written for this demo. They are intentionally cross-referenced — the FDA correspondence references the protocol, the protocol references the FDA correspondence, the MSA references the NDA — so multi-document synthesis questions have real answers.
MEDIGEN-CMC-PHASE-2-SUMMARY
CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) SUMMARY — PHASE 2 SUPPLY
Other9 chunks
MEDIGEN-COLLABORATION-AGMT-STANFORD-2025
SPONSORED RESEARCH AND COLLABORATION AGREEMENT
Other14 chunks
MEDIGEN-FDA-BRIEFING-PHASE-3
SPONSOR BRIEFING DOCUMENT — END-OF-PHASE-2 / PRE-PHASE-3 (TYPE B)
FDA correspondence8 chunks
MEDIGEN-FDA-CLINICAL-HOLD-2024
SECTION II — SPONSOR RESPONSE (SUBMITTED FEBRUARY 5, 2024)
FDA correspondence8 chunks
MEDIGEN-FDA-IR-2024-MEDIGEN-1234
RESPONSE TO FDA INFORMATION REQUEST
FDA correspondence8 chunks
MEDIGEN-FDA-SAFETY-UPDATE-Q1-2025
QUARTERLY AGGREGATE HEPATOTOXICITY UPDATE — Q1 2025
FDA correspondence8 chunks
MEDIGEN-FDA-TYPE-B-2023-PRE-IND
MEDIGEN QUESTIONS AND FDA RESPONSES
FDA correspondence8 chunks
MEDIGEN-FDA-TYPE-C-2024-DOSE
SPONSOR QUESTIONS AND FDA RESPONSES
FDA correspondence9 chunks
MEDIGEN-IP-DISCLOSURE-MG-1234-COMBO-2025
The invention covers the therapeutic combination of MEDIGEN-1234 (MG-1234), a selective mineralocorticoid receptor antag
Other9 chunks
MEDIGEN-LICENSE-AGREEMENT-LUMEN-2024
EXCLUSIVE OPTION AND LICENSE AGREEMENT
Other14 chunks
MEDIGEN-MEDICAL-AFFAIRS-KOL-FEEDBACK-2025
MEDICAL AFFAIRS — KOL ADVISORY BOARD SUMMARY
Other10 chunks
MEDIGEN-MSA-AURORA-2024
MASTER SERVICES AGREEMENT
MSA9 chunks
MEDIGEN-MSA-CYGNUS-2023
MASTER SERVICES AGREEMENT
MSA8 chunks
MEDIGEN-MSA-HELIOS-2024
MASTER SERVICES AGREEMENT
MSA8 chunks
MEDIGEN-MSA-VEGA-2024
MASTER SERVICES AGREEMENT
MSA5 chunks
MEDIGEN-NDA-2024-008
MUTUAL NON-DISCLOSURE AGREEMENT
NDA10 chunks
MEDIGEN-NDA-2024-009
MUTUAL NON-DISCLOSURE AGREEMENT
NDA10 chunks
MEDIGEN-NDA-2025-001
MUTUAL NON-DISCLOSURE AGREEMENT
NDA9 chunks
MEDIGEN-NONCLINICAL-SUMMARY-MG-1234
The nonclinical package establishes adequate safety margins to support the ongoing Phase 2 program. The hERG margin (44x
Other8 chunks
MEDIGEN-PATENT-FAMILY-MAP
PATENT FAMILY MAP — INTERNAL IP SUMMARY (MG-1234 FRANCHISE)
Patent11 chunks
MEDIGEN-PATENT-US-12345678-EXCERPT
PATENT — INDEPENDENT CLAIMS EXCERPT
Patent6 chunks
MEDIGEN-PATENT-US-12456789-EXCERPT
PATENT — METHOD OF TREATMENT CLAIMS EXCERPT
Patent10 chunks
MEDIGEN-PATENT-US-12567890-EXCERPT
PATENT — CRYSTALLINE FORM CLAIMS EXCERPT
Patent9 chunks
MEDIGEN-PHARMACOVIGILANCE-REPORT-2024-H2
The overall safety profile of MG-1234 during H2 2024 remains consistent with the profile characterized at the time of cl
Other9 chunks
MEDIGEN-PROTOCOL-AMENDMENT-LOG
PROTOCOL AMENDMENT LOG
Clinical protocol8 chunks
MEDIGEN-PROTOCOL-MG-1234-101-PHASE1-SAD
CLINICAL STUDY PROTOCOL AND RESULTS SUMMARY
Clinical protocol8 chunks
MEDIGEN-PROTOCOL-MG-1234-202-V3.0
CLINICAL STUDY PROTOCOL — SUMMARY
Clinical protocol9 chunks
MEDIGEN-PROTOCOL-MG-1234-202-V3.1
CLINICAL STUDY PROTOCOL — SUMMARY
Clinical protocol8 chunks
MEDIGEN-REG-STRATEGY-MG-1234-2025
(e) Phase 2 dose-ranging study MG-1234-202 (NCT06492210) initiated October 2024 under Protocol v3.1 (Document ID: MEDIGE
Other10 chunks
MEDIGEN-SOW-CYGNUS-2024-MG-1234
5.1 Service Fees. Total CRO service fees for the Services described herein shall not exceed four million two hundred tho
Other8 chunks